On-line Registration

Anthony Fyles, MD FRCPC

Anthony Fyles is the Department of Radiation Oncology Breast Site leader, and is Professor in the Departments of Radiation Oncology and Obstetrics and Gynecology at the University of Toronto. He did his MD degree and postgraduate training in Radiation Oncology at the University of Toronto and Royal Marsden Hospital. Dr. Fyles has research interests in translational and drug development clinical trials in gynecologic cancer, clinical studies of the tumour microenvironment, and clinical trials in breast cancer.

Meredith Giuliani, MD Med FRCPC

Meredith Giuliani is an assistant professor in the University of Toronto, Department of Radiation Oncology and a radiation oncologist in the Radiation Medicine Program at the Princess Margaret Cancer Centre. She received her MBBS qualification from the University of London, England and her Master’s of Education from the University of Toronto. She completed her residency training at the University of Toronto. She is the Chair of the Canadian Association of Radiation Oncology’s Education Committee and the Director of Undergraduate Education for the Department of Radiation Oncology at the University of Toronto, the Medical Director of Education for Princess Margaret Cancer Centre and the Cancer Care Ontario Smoking Cessation Champion for Toronto Central South. Her research interests include education technology development, outcomes research in lung cancer and curriculum development.

David Jaffray, PhD

David Jaffray graduated from the University of Alberta with a B.Sc. in Physics (Hons.) in 1988 and completed his Ph.D. in the Department of Medical Biophysics at the University of Western Ontario in 1994. Following graduation, he took a position as Staff Physicist in the Department of Radiation Oncology at William Beaumont Hospital in Michigan where he instigated a direction of research that garnered funding from the NIH and from congressionally-directed funding programs. Dr. Jaffray became a Board Certified Medical Physicist (ABMP – Radiation Oncology) in 1999. In 2002, Dr. Jaffray joined the Princess Margaret Hospital in Toronto as Head of Radiation Physics and a Senior Scientist within the Ontario Cancer Institute. David holds the Fidani Chair in Radiation Physics, is the Director of the TECHNA Institute for Health Technology Development at the University Health Network and recently became the Executive Vice President of Technology and Innovation at the University Health Network. He is a Professor in the Departments of Radiation Oncology, Medical Biophysics, and Institute for Biomaterials and Biomedical Engineering at the University of Toronto. His primary area of research has been in the development and application of image-guided therapy. He has over 5 patents issued and several licensed, including, kilovoltage cone-beam computed tomography for image-guided radiation therapy. Dr. Jaffray has >200 peer-reviewed publications in the field, >100 invited lectures, and holds numerous peer-review and industry sponsored research grants. He sits on numerous scientific and research boards and has contributed to the NIH and CIHR grant review process for several years. He is an active member of the AAPM and teaching role in workshops and annual meeting of the American Society of Therapeutic Radiation Oncology (ASTRO). He has an active interest in commercialization and led the development of a variety of commercial products including software and hardware for QA and the development of small animal irradiator systems for basic research. He has successfully supervised over 20 graduate students and fellows.

Otis Webb Brawley, MD MACP FASCO FACE

Otis Webb Brawley is an acknowledged global leader in the field of cancer prevention and control. As the chief medical and scientific officer and executive vice president of the American Cancer Society, he is responsible for promoting the goals of cancer prevention, early detection, and quality treatment through cancer research and education. He champions efforts to decrease smoking, improve diet, and provide the critical support cancer patients need. He also guides efforts to enhance and focus the Nation’s research program, upgrade the Society’s advocacy capacity, and concentrate community cancer control efforts in areas where they will be most effective. Dr. Brawley currently serves as professor of hematology, oncology, medicine and epidemiology at Emory University. He is also a medical consultant to the Cable News Network (CNN). From April of 2001 to November of 2007, he was director of the Georgia Cancer Center at Grady Memorial Hospital in Atlanta, and deputy director for cancer control at the Winship Cancer Institute at Emory University. He previously served as a member of the Society’s Prostate Cancer Committee, co-chaired the U.S. Surgeon General’s Task Force on Cancer Health Disparities, and filled a variety of positions at the National Cancer Institute (NCI), most recently serving as Assistant Director.

Dr. Brawley has served on a number of advisory committees including: the NIH Committee on Women’s Health; the Centers for Disease Control and Prevention Advisory Committee on Breast Cancer in Young Women; the Centers for Disease Control and Prevention Breast and Cervical Cancer Early Detection and Control Advisory Committee; and the Food and Drug Administration Oncologic Drug Advisory Committee. He chaired the NIH Consensus Panel on the Treatment of Sickle Cell Disease. He has been listed by Castle Connelly as one of America’s Top Doctors for Cancer. Among numerous other awards, he was a Georgia Cancer Coalition Scholar and received the Key to St. Bernard Parish for work in the U.S. Public Health Service in the aftermath of Hurricane Katrina. He is a fellow of the American Society of Clinical Oncology, a Fellow of the American College of Epidemiology and one of less than 1300 physicians to be named a Master of the American College of Physicians in its more than 100 year history. Dr. Brawley is also a member of the National Academy of Medicine.

Dr. Brawley graduated from the University of Chicago, Pritzker School of Medicine; trained in internal medicine at Case-Western Reserve University, and in medical oncology at the National Cancer Institute.

Sumit Gupta, MD PhD FRCPC

Sumit Gupta is a Staff Oncologist and Clinician Investigator at the Hospital for Sick Children, an Assistant Professor at both the Faculty of Medicine and the Institute for Health Policy, Management and Evaluation at the University of Toronto, and an Adjunct Scientist with the Cancer Research Program at the Institute for Clinical Evaluative Sciences. He completed a PhD in Clinical Epidemiology from the University of Toronto, during which time he was supported by a CIHR Fellowship Award. He is currently one of the chairs of an ongoing Lancet Oncology Commission on Sustainable Pediatric Cancer Care in low and middle income countries. Sumit has worked extensively with pediatric oncologists and policymakers throughout Latin America, the Caribbean, and India. He currently holds grant funding from The Garron Family Cancer Centre, Alex’s Lemonade Stand, CIHR and the Canadian Cancer Society Research Institute.

Edward L. Trimble, MD MPH

In 2011 Dr. Harold Varmus, then Director of the US National Cancer Institute (NCI) appointed Dr. Trimble the founding Director of NCI’s new Center for Global Health (CGH). Under Dr. Trimble’s leadership CGH has become the coordinating point for NCI’s work to strengthen global cancer research, to train future generations of global cancer researchers, and to help translate research into policy for cancer control. NCI CGH has been recognized worldwide for its work in the development of affordable cancer technology, national cancer control planning, and training.

From 1991 to 2011 Dr. Trimble worked in NCI’s Division of Cancer Treatment and Diagnosis, with responsibility for national and international NCI-sponsored treatment trials in gynecologic cancer, as well as cancer trials for the elderly, adolescents and young adults, international collaboration in cancer clinical trials, and strengthening assessment of patient-reported outcomes and health-related quality of life in cancer trials. He spearheaded the NCI’s Clinical Announcements regarding chemoradiation for cervical cancer (1999) and intraperitoneal chemotherapy for ovarian cancer (2006), both of which changed the standard of care for women with gynecologic cancer. For his work at the US NCI Dr. Trimble has received two Public Health Service Commendation Medals, six NIH Merit Awards, and the NCI Director’s Gold Star Award.

Dr. Trimble graduated from Harvard University (BA), the Johns Hopkins University School of Medicine (MD), and the Johns Hopkins University Bloomberg School of Public Health (MPH). He trained in obstetrics/gynecology at Vanderbilt University Medical Center and in gynecologic oncology at Memorial Sloan-Kettering Cancer Center. He is board-certified in obstetrics and gynecology, as well as in gynecologic oncology, by the American Board of Obstetrics and Gynecology.

Sir George Alleyne

Sir George Alleyne, a native of Barbados, became Director of the Pan American Health Organization (PAHO), Regional Office of the World Health Organization (WHO) on 1 February 1995 and completed a second four-year term on 31 January 2003. In 2003 he was elected Director Emeritus of the PASB. From February 2003 until December 2010 he was the UN Secretary General’s Special Envoy for HIV/AIDS in the Caribbean. In October 2003 he was appointed Chancellor of the University of the West Indies. He currently holds an Adjunct professorship on the Bloomberg School of Public Health, Johns Hopkins University.

Dr. Alleyne has received numerous awards in recognition of his work, including prestigious decorations and national honors from many countries of the Americas. In 1990, he was made Knight Bachelor by Her Majesty Queen Elizabeth II for his services to Medicine. In 2001, he was awarded the Order of the Caribbean Community, the highest honor that can be conferred on a Caribbean national.

Sanchia Aranda, RN PhD

Professor Sanchia Aranda was appointed as CEO of Cancer Council
Australia in August 2015. In this role Sanchia leads cancer policy and advocacy development, ensuring a strong evidence base is used to inform cancer control in Australia. She also holds academic appointments with the School of Health Sciences, University of Melbourne and the Faculty of Nursing, University of Sydney and is a research fellow at the Peter MacCallum Cancer Centre. She has 38 years’ experience in cancer control and has held roles in healthcare, research, tertiary education and government prior to joining the not-for-profit sector. She has held significant leadership roles in Australian Cancer Control, including 8 years on the Advisory Council for Cancer Australia (2006-2015).

Sanchia also has extensive international cancer control experience, with 16 years on the board of the International Society of Nurses in Cancer Care, including 4 as President (2006-2010). She is the President for the Union for International Cancer Control and has been on the board of UICC for 6 years. She is also a board member for the International Collaboration on Cancer Reporting. Her contributions to cancer control have been recognized nationally and internationally through awards and keynote speaker invitations. In 2013 she was named the 4th Peter MacCallum Cancer Centre Distinguished Fellow for her contributions to Cancer Nursing and in 2016 received the International Society of Nurses in Cancer Care Distinguished Merit award.

Rifat Atun

Rifat Atun is Professor of Global Health Systems at Harvard University and Director of the Health Systems Cluster. He is the Faculty Chair for the Harvard Ministerial Leadership Initiative. In 2006-2014 he was Professor of International Health Management at Imperial College London.

In 2008-12 Professor Atun served as a member of the Executive Management Team of the Global Fund to Fight AIDS, Tuberculosis and Malaria in Switzerland as the Director of the Strategy, Performance and Evaluation.

Professor Atun’s research focuses on global health systems, global health financing, and innovation in health systems. He has worked extensively with governments, the UK DFID, the World Bank, World Health Organization, and other international agencies to design, implement and evaluate health system reforms.

Dr. Atun studied medicine at University of London as a Commonwealth Scholar and undertook his postgraduate medical studies and MBA at University of London and Imperial College London. He is a Fellow of the Faculty of Public Health of the Royal College of Physicians (UK), a Fellow of the Royal College of General Practitioners (UK), and a Fellow of the Royal College of Physicians (UK).

Mary Hooey, CMP

Mary Hooey has been employed at the Princess Margaret Cancer Centre since 1997 and is currently the Business Administration Manager. She supports educational program initiatives and activities for the Cancer Education Program. Mary has more than 20 years’ experience in event planning and sits on various committees for local, national and international conference planning committees. In 2016, she received the Excellence in Education Support Award. In her spare time, she enjoys volunteering for fundraising activities, bike riding and has rode in the Ride to Conquer Cancer for 7 years!

Amit Oza MBBS, MD, FRCPC

Amit Oza MBBS, MD, FRCPC is Head of the Department of Medical Oncology & Hematology, and Medical Director of the Cancer Clinical Research Unit at Princess Margaret Cancer Centre (PM). He is also co-Director of the Drug Development Program at PM, Scientist at the Ontario Cancer Institute, and Professor of Medicine at University of Toronto. Dr. Oza has been PI and co-investigator in >100 phase I, II and III trials for gynecological cancer and advanced colorectal malignancies. Under his direction, the gynecology group is one of the largest ovarian cancer (OC) clinical trials groups consistently accruing >30% of all patients seen onto clinical trials (>120/yr) at PM. Since 2011, he has obtained >$26.9M in peer-reviewed funding and has published >180 articles (all types) including the New England Journal of Medicine (IF=53); Lancet Oncology (IF=16), and Journal of Clinical Oncology (IF=16.4).

Miriam Schneidman

Miriam Schneidman is a Lead Health Specialist in the Africa Region of the World Bank. She has more than 35 years of experience working on health and human development issues in the Africa and Latin America and Caribbean Regions of the World Bank.

Schneidman has led the design and development of investment operations in Africa (e.g. Burundi, Burkina Faso, Cameroon, Democratic Republic of Congo, Kenya, Rwanda, Nigeria, Tanzania, and Uganda) and Latin America and the Caribbean (e.g. Bolivia, Colombia, Haiti). She was extensively involved in the World Bank’s Multi-Country HIV/AIDS Program for Africa (MAP), leading the roll-out of AIDS treatment programs, brokering partnerships, and managing several operations, including the Burkina and Rwanda MAPs. Over the past few years she has led a unique regional project in East Africa to strengthen diagnostic and surveillance systems. Most recently, she organized a South-South Knowledge Exchange to support countries in East and Southern Africa to share lessons and experiences in cancer care and control. In the past she worked extensively on family planning, reproductive health, and demographic issues.

Schneidman has written on the subject of vulnerable youth (Targeting At-Risk Youth, 1996), demographic issues (Mortality and Fertility Trends in Zaire, 1990), co-authored books and articles on women’s health (Women’s Health in Latin America and the Caribbean, 2001), performance based financing (Performance Incentives for Global Health, 2009), and laboratory systems (Laboratory Professionals in Africa: The Backbone of Quality Diagnostics, 2014) and cancer care and control (Cancer Care and Control South-South Knowledge Exchange, 2015).

Schneidman currently represents the World Bank on the Stop TB Partnership Coordinating Board. In the past she served as a member of the Center for Global Development Performance-Based Incentives Working Group and the Harvard Global Task Force on Expanded Access to Cancer Care and Control. Schneidman holds degrees in Economics from the University of Maryland and in Public Health from The Johns Hopkins University. She is fluent in French, Spanish and Romanian.

Dr David Collingridge

Dr David Collingridge has been Editor-in-Chief of The Lancet Oncology since March 2002, and is also the Publishing Director for The Lancet’s Specialty Journals. Prior to his appointments at The Lancet, he gained a PhD in Tumour Biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, Hammersmith Hospital, London, UK. Dr Collingridge has published numerous peer-review articles, editorials, opinion pieces, and news reports, and has co-authored a text book on radiobiology. He currently also holds the position of Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA.

Rengaswamy Sankaranarayanan, MD

Rengaswamy Sankaranarayanan was trained as radiation and clinical oncologist in the University of Kerala, India and had post-doctoral training at the Pittsburgh Cancer Institute, USA and the MRC Biostatistics Unit, Cambridge, UK. After working in primary care, clinical oncology and cancer control in India for about 11 years, Dr. Sankaranarayanan joined the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO) in 1993, where he was the Head of the Early Detection and Prevention Section until 2014 and is currently the Special Advisor on Cancer Control and Head of the Screening Group. He is committed to research, training, program development and technical assistance in early detection and cancer control, particularly in low- and middle income countries (LMICs). He has conceived, conducted and coordinated multinational studies in Asia, Africa and Latin America addressing feasible, affordable and effective methods of early detection and control of cervix, breast, colorectal and oral cancers and has also addressed survival outcomes from major cancers in LMICs. He has provided technical support to national cancer control programs and national screening programs in several LMICs. Dr Sankaranarayanan has taught in over 70 international courses on cancer early detection and control. He is an author in more than 260 papers in international peer-reviewed journals.

Anthony Miceli

Anthony Miceli is a strategic advancement professional with 20 years of experience in creating revenue growth in the not for profit sector. Currently holds the position of Executive Director, Corporate and Foundation Relations at the University of Toronto. Previous to U of T, Anthony was the Vice President of Development for the Canadian Breast Cancer Foundation and the VP, Business Development and Marketing, Special Olympics Canada. Throughout his career, Anthony’s primary focus has been to lead the corporate development efforts for a variety of charitable organizations.

In 2004, after identifying a tremendous need within the non-profit market, Anthony created jla consulting, an agency that exclusively focused on supporting the strategic fund development and marketing needs of small to mid-sized charities across the country. Anthony has had the privilege and opportunity to provide leadership for a diverse range of organizations including; international development agencies, national membership organizations, and a vast array of local community groups.

In his current role, Anthony works with colleagues across all three campuses to actively manage the university’s sponsorship and philanthropic interests amongst U of T’s institutional partners.

Gary Rodin, MD, FRCPC

Gary Rodin is the Joint University of Toronto/University Health Network Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care and is Head of the Department of Supportive Care at the Princess Margaret Cancer Centre in Toronto.

Dr. Rodin is the Director of the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC) and a Professor of Psychiatry at the University of Toronto. He is a clinician-investigator who has published widely on the psychiatric and psychosocial aspects of cancer and other medical illnesses. Under his leadership, the Department of Supportive Care at the Princess Margaret has now achieved an international reputation for its academic and clinical excellence.

Dr. Rodin has authored texts on Depression in the Medically Ill, and on the Psychiatric Aspects of Transplantation and is currently leading research on the psychological impact of advanced and terminal disease in affected patients and their families.

Hellen Gelband

Hellen Gelband is Associate Director for Policy at the Center for Disease Dynamics, Economics & Policy (CDDEP). Her work spans infectious disease, particularly malaria and antibiotic resistance, and non-communicable disease policy, mainly in low- and middle-income countries. Before joining CDDEP, she conducted policy studies at the (former) Congressional Office of Technology Assessment, the Institute of Medicine of the U.S. National Academies, and a number of international organizations. She is an editor in the Cochrane Infectious Diseases Group and an editor of Disease Control Priorities, 3rd edition. At CDDEP, she has led the Global Antibiotic Resistance Partnership (GARP) since its inception in 2008.

Eduardo L. Franco, MPH, DrPH, FRSC, FCAHS, OC

He is James McGill Professor and Chairman, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. Since 1985, he has conducted epidemiologic research on the causes of cancer and on the means to prevent it or to improve patient survival, topics on which he has published more than 440 articles, 60 book chapters, and two books. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and using this knowledge to prevent this cancer via vaccination and improved screening strategies. For his work on these topics, he received Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology (2010) and from the International Papillomavirus Society (2015), the Women in Government’s (US) Leadership Award (2008), the Canadian Cancer Society’s Warwick Prize (2004), and the McLaughlin-Gallie Award from the Royal College of Physicians and Surgeons of Canada (2011). He mentored than 100 graduate students and post-doctoral fellows. He is the Editor-in-Chief of Preventive Medicine and has served in the editorial boards of several top-tier journals in oncology and epidemiology. He is Officer of the Order of Canada (2016) and Fellow of the Royal Society of Canada (2011) and of the Canadian Academy of Health Sciences (2012).

Ophira Ginsburg, MSc MD FRCPC

Dr. Ginsburg is medical oncologist with expertise in cancer genetics, epidemiology, prevention, and screening. Her research spans more than a decade in global cancer control and women’s health equity. Since 2004, she has developed a program of population intervention research and training in global cancer control, with projects in Vietnam, Bangladesh, and Tanzania. She is principal investigator on studies of population differences in breast cancer risk factors; and of public health interventions to improve access to cancer services for women in low-income countries, and women from ethno-cultural minority communities in North America.

She is an Advisor to the National Cancer Hospital and National Institute for Cancer Control of Vietnam, and is a faculty member of the Institute of Cancer Policy, King's College London and the James P Grant School of Public Health at BRAC University, Bangladesh. She serves on several NGO advisory boards including Young Professionals Chronic Disease Network (U.S.), Global Focus on Cancer (U.S.), and is a founding member of WEMA, Women's Health Equity Through Mobile Approaches (Canada).

From October 2015- November 2016, Dr Ginsburg worked in Geneva Switzerland, as the Cancer Management Lead for the World Health Organization. In March 2017 she began a new post as Director of the High Risk Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, and Associate Professor in the Department of Population Health, NYU School of Medicine.

Dr. Ginsburg has authored 58 peer-reviewed articles, including a three-part commissioned series for The Lancet, “Health, equity, and women’s cancers”. A global effort with 40+ authors from 18 countries, the Series was published along with invited commentaries at the World Cancer Congress (Paris, Nov 2, 2016). She is a founding editorial board member of the Journal of Global Oncology (ASCO) and Journal of Cancer Policy (Elsevier).

May Abdel-Wahab

Dr May Abdel-Wahab is the Director of the Division of Human Health at the International Atomic Energy Agency, Vienna Austria. She has over 30 years of patient care, teaching and research experience in radiation oncology. Before joining IAEA she was section head of GI Radiation Oncology at the Cleveland Clinic, USA and Professor at the Cleveland Clinic Lerner School of Medicine, Case Western University. Her research focused on evaluating radiation therapy for prostate and GI cancers as well as quality assurance and access in radiotherapy. She served on various National and International committees, such as the UN inter-agency Task Force (UNIATF) on Non-Communicable Diseases (NCDs), as Chair of the ASTRO Committee for Healthcare Access & Training, as Co-Chair IHE-RO planning committee and on the UN Joint Programme on Cervical Cancer Control Steering committee, among others. She has published over 150 scientific publications, including scientific papers , abstracts and book chapters and has served on several advisory boards and professional journal editorial boards. As scientific secretary , she organized numerous national symposia and scientific meetings. She was honoured as a fellow of the American board of Radiology, American Society of Radiation Oncology and was on the Best doctors in America listing. She has also served on expert panels such as the ACR appropriateness criteria panels in prostate cancer and gastrointestinal cancers. Her interests related to global health are in cancer control, healthcare access and training, as well as novel solutions to disparity and diversity issues in radiation oncology.

Anil D'Cruz

Anil K D’cruz is Director at the Tata Memorial Hospital, Mumbai, India and Professor and Surgeon in the Department of Head and Neck Surgery. He graduated from St.John’s Medical College, Bangalore in 1984 & went on to complete his Masters in general surgery at the Mumbai University. He is also a Diplomate of the National Board, New Delhi. In recognition of his professional standing in the field of Surgery, he was awarded the Honorary FRCS from the Royal College of Surgeons, London.

Dr. D’Cruz has over 30 years experience in the field of Surgical Oncology focussing primarily on head and neck cancers. His major areas of interest are management of neck metastasis, conservative laryngeal surgery, cancers of the oral cavity, thyroid, quality of life issues and global health. He is actively involved in research and plays a pivotal role in a number of trials. As principal investigator, he has successfully published results of a prospective randomized controlled trial evaluating the role of elective neck dissection in the management of early oral cancers that is practice defining. In addition, he has been principal investigator of a Phase I trial evaluating the role of Interstitial Photodynamic Therapy (PDT) in advanced cancers and was the Global Principal Investigator for a trial evaluating the role of PDT in recurrent, refractory head and neck tumors. He is also the principal investigator of multicentric, multinational trials studying the role of targeted therapy in head and neck cancers in the concurrent, adjuvant and the palliative setting. He has been involved in research on the use of curcumin, proteomics, gene therapy in head and neck cancer.

Dr. D’Cruz has leadership position in a number of cancer organizations. He is on the Board of Directors on the Union International on Cancer Control, Geneva as well as Governing Council, Foundation of Head and Neck Oncology, India. He is also on the Governing Board/Scientific Advisory Board of various leading institutions such as Gulf Medical University, All India Institute of Medical Sciences, Rishikesh, National Institute of Biomedical Genomics, Kalyani amongst others. He has been past-president of the Asian Society of Head and Neck Oncology, Foundation of Head and Neck Oncology, India; Task force, Department of Biotechnology, Government of India, and Cancer guidelines, Indian Council of Medical Research.

Dr D’cruz is a member of numerous professional bodies in the country which include, The Indian Society of Surgical Oncology, Association of Surgeons of India, Indian Society for Cancer Research, Indian Association of Surgical Oncology, Foundation of Head and Neck Oncology, Indian Society of Head and Neck Oncology and the Action council for Tobacco Control.

Dr D’Cruz has over 200 peer reviewed publications, and chapters to his name. He is an editor of a two-volume book on Head and neck surgery and also the to-be-released Manual of Clinical Oncology and Hamilton Bailey Clinical Signs. He has delivered over 300 invited lectures and orations and has been visiting professor to several institutions, both nationally and internationally. He is a member of the Editorial Board of Head Neck journals and also is a reviewer for several scientific journals both national and international.

Felicia Marie Knaul

Felicia Marie Knaul is the Director of the University of Miami Institute for Advanced Study of the Americas and a Professor at UM’s Miller School of Medicine. She maintains a strong program of research and advocacy in Latin America, especially in Mexico, where she is the Senior Economist at the Mexican Health Foundation and Founding President of Tómatelo a Pecho, A.C. Dr. Knaul is also the President (2016-18) of the Latin American Union against Women’s Cancers (ULACCAM).

As a result of her breast cancer experience, in 2008 Dr. Knaul founded Tómatelo a Pecho, a Mexico-based non-profit agency that promotes research, advocacy, awareness, and early detection in Latin America. She has lectured globally on the challenge of breast cancer in low and middle-income countries, both as patient-advocate and health systems researcher. She recounts her personal experience in Tómatelo a Pecho (Grupo Santillana, 2009) and Beauty without the Breast (Harvard University Press/ Harvard Global Equity Initiative, 2013). Her story and her work have been featured in Reforma, The Miami Herald, The Lancet, Science, WHO Bulletin, Newsweek en Español, and Cancer Today.

Dr. Knaul has designed, created and coordinated several research networks. As Director of the Harvard Global Equity Initiative, she founded and directed the Global Task Force on Expanded Access to Cancer Care and Control, serving as lead author and co-editor of the task force’s publication Closing the Cancer Divide: An Equity Imperative (Harvard University Press/ Harvard Global Equity Initiative, 2012), and was a member of the Global Task Force on Radiotherapy for Cancer Control (GTFRCC), taking a leadership role in the global reports that were produced. From 2012-2015, she was a member of the Lancet Commission on Women and Health and a leading co-author of its June 2015 report. Since 2014 she is the Chair of the Lancet Commission on Global Access to Palliative Care and Pain Control. Her areas of research are focused on global health and include cancer and especially breast cancer in low- and middle-income countries, women and health, health system strengthening and reform, health financing, and access to pain control and palliative care.

Dr. Knaul has produced more than 190 academic and policy publications, authored and lead-edited academic books, and serves on the advisory board or editorial board of several medical and health care publishers, including The Lancet Global Health and the Journal of Global Oncology, among others. She has also served on numerous boards, including the Union for International Cancer Control (2010-2014). Dr. Knaul received M.A. and Ph.D. degrees in economics from Harvard University and a B.A. in international development from the University of Toronto.

She and her husband, Dr. Julio Frenk, have two children, Hannah Sofia (20 and studying chemistry) and Mariana Havivah (12). Her mother Marie and brother Jonathan live in Canada.

Ryan Lindsay

Ryan Lindsay is the Senior Development Officer at the Dalla Lana School of Public Health, University of Toronto, where he works with faculty and alumni to secure funding for research, student scholarships and advance the mission of the School.

Ryan received his BA Honours Sociology with Business Administration in 2000 from Wilfred Laurier University. He completed teachers’ college in New Zealand, has a certificate in Strategic Communications from University of Toronto, and is currently pursuing his Masters of Education at University of Toronto.

In his spare time Ryan plays squash, Ultimate Frisbee and he runs a couple of not-for-profits that support Waldorf education in Canada and Central America.

Cindy Gauvreau

Cindy Gauvreau is a health economist at the Canadian Partnership Against Cancer, where she uses the OncoSim microsimulation model to study population level impacts of Canadian cancer control strategies. While a post-doctoral fellow and economist with the Centre for Global Health Research at St. Michael’s Hospital in Toronto, she coordinated publication of the Disease Control Priorities Network book "DCP3:

Cancer", a volume authored by international groups of cancer researchers and aimed at cancer control policy-making in low- and middle-income countries. Her research interests include cost-effectiveness analysis of cancer screening strategies, tobacco control and infectious disease control, in both Canada and low- and middle-income countries.

Cindy has a PhD in Health Services Research from the Institute of Health Policy, Management and Evaluation and an MA in Economics from the University of Toronto.

Anna Dare MBChB PhD

Anna Dare MBChB PhD is a general surgery resident at the University of Toronto and a post-doctoral fellow at the Centre for Global Health Research, St Michael’s Hospital. Her major interest is expanding access to surgical care in low- and middle-income countries (LMICs) in order to meet emerging health challenges. Her research examines the relationships between surgical access, coverage and outcomes using large-scale epidemiological studies and geostatistical methods. Originally from New Zealand, Anna received her medical degree from the University of Auckland. She then completed her PhD at the University of Cambridge, England as a Commonwealth Scholar. Anna has served as a Commissioner on the Lancet Commission on Global Surgery and the Lancet Oncology Commission on Global Cancer Surgery, and is an author for the Disease Control Priorities Project (3rd edition) Cancer Volume. Her work has taken her throughout the Western Pacific, South Asia, West Africa and most recently to Canada.

Rama Khokha

Dr. Khokha is a highly respected leader in cancer biology research. She is a Senior Scientist at PM Cancer Centre and Professor in the Department of Medical Biophysics at the University of Toronto (UT). She has published over 149 peer-reviewed articles in prestigious journals, including Nature Genetics and Nature Cell Biology, and has been invited to speak at high-profile international conferences, including Gordon Research Conferences and Keystone Symposia. In recognition of her outstanding achievements in cancer research, Dr. Khokha was awarded the Robert L. Noble Prize from the Canadian Cancer Society in 2015.

In addition to her research, Dr. Khokha is actively involved in the academic and research community. She has held several leadership positions, including Acting Chair of UT’s Department of Medical Biophysics, Chair of the Appointments and Recruitment Committee (PM Cancer Centre) and Chair of several grant review panels at national funding agencies. She has also organized scientific meetings on cancer and new genome-based experimental approaches.

Dean Jamison

Dean Jamison is Professor Emeritus of Global Health at the University of California, San Francisco and at the University of Washington, Seattle. In 2006-2008 he served as the T. & G. Angelopoulos Visiting Professor of Public Health and International Development in the Harvard Kennedy School and the Harvard School of Public Health. Previously, Dean had been at University of California, Los Angeles (1988-2006) and at the World Bank (1976-1988). His last position at the World Bank was Director, World Development Report Office and lead author for the Bank’s 1993 World Development Report, Investing in Health. His publications are in the areas of economic theory, public health and education. Jamison studied at Stanford (M.S., Engineering Science) and at Harvard (Ph.D., Economics, under K.J. Arrow). In 1994 he was elected to membership in the National Academy of Medicine. Jamison was recently co-first author with Lawrence Summers of ‘Global Health 2035’, the report of the Lancet Commission on Investing in Health (The Lancet, December 2013). His publications are in the areas of economic theory, public health and education.

Mary Gospodarowicz, MD FRCPC FRCR(Hon) FFRCSI(Hon)

Mary Gospodarowicz is Professor of Radiation Oncology at the University of Toronto, the Medical Director of the Princess Margaret Cancer Centre at the University Health Network, and the Regional Vice President of Cancer Care Ontario. She is past Chair of Radiation Oncology at the University of Toronto. She holds specialty certifications in internal medicine, radiation oncology, and medical oncology and her clinical practice involves lymphomas and genitourinary cancers. Her research focused on clinical trials evaluating radiation therapy, image-guided precision radiotherapy, and cancer survivorship. Her current interests include global cancer control, global access to radiotherapy, and quality cancer care.

Professor Gospodarowicz is Past-President of the Union for International Cancer Control (UICC). She proudly participates in the work of the Global Task Force on Cancer Care and Control of Harvard Global Equity Initiative and the HGEI-Lancet Commission on Global Access to Pain Control & Palliative Care. Under the auspices of UICC and Lancet Oncology, the Global Task Force on Radiotherapy produced a seminal report on ‘Expanding the global access to radiotherapy” that provided evidence for the demand, efficacy, and cost effectiveness of radiotherapy.

Prabhat Jha, OC, MD, DPhil, FCAHS

Professor Prabhat Jha is an Endowed Professor in Global Health and Epidemiology at the University of Toronto and Canada Research Chair at the Dalla Lana School of Public Health, and the founding Director of the Centre for Global Health Research. Professor Jha is a lead investigator of the Million Death Study in India, which quantifies the causes of premature mortality in over 2 million homes. His publications on tobacco control have enabled a global treaty now signed by over 180 countries. He founded the Statistical Alliance for Vital Events, which focuses on reliable measurement of premature mortality worldwide.

Earlier, Professor Jha served in senior roles at the World Health Organization and the World Bank. He was made an Officer of the Order of Canada in 2012. Professor Jha holds an M.D. from the University of Manitoba and a D.Phil. from Oxford University, where he studied as a Rhodes Scholar